Wall Street analyst estimates for Abivax S.A. (ABVX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-09-21 | $-0.92 | ||
| 2026-05-22 | $-0.71 | $-1.07 | +33.6% |
| 2026-03-23 | $-1.19 | $-1.70 | +30.0% |
| 2025-12-15 | $-2.47 | $-0.79 | -214.3% |
| 2025-09-08 | $-0.86 | $-0.90 | +4.4% |
| 2025-06-02 | $-0.97 | $-0.76 | -28.3% |
| 2025-03-24 | $-1.68 | $-1.59 | -5.8% |
| 2024-11-14 | $-0.70 | $-0.70 | +0.3% |
Valuation Ratios
| Price / Book | 15.11 |
| EV / EBITDA | -24.97 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $127000 | $10000 | $18000 | $2000 | $63000 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $14.6M | $14.5M | $15.4M | $28.2M | $33.8M | $45.5M | $50.8M | 0 | 0 | 0 |
| Gross Profit | -$14.5M | -$14.5M | -$15.4M | -$28.2M | -$33.8M | -$45.5M | -$50.8M | 0 | 0 | 0 |
| Research & Development | 0 | 0 | 0 | 0 | 0 | $47.8M | $48.3M | $103.2M | $146.5M | $177.8M |
| Selling, General & Admin | $3.6M | $3.8M | $4.3M | $4.9M | $5.6M | $5.6M | $7.5M | $28.8M | $38.9M | $72.9M |
| Operating Expenses | $3.7M | -$347000 | $3.7M | $5.1M | $4.2M | -$4.1M | $14.1M | $127.4M | $173.0M | $246.1M |
| Operating Income | -$18.2M | -$14.2M | -$19.1M | -$33.3M | -$38.0M | -$41.4M | -$64.8M | -$127.4M | -$173.0M | -$246.1M |
| EBITDA | -$17.9M | -$14.0M | -$19.2M | -$33.2M | -$38.0M | -$38.6M | -$53.3M | -$133.2M | -$162.7M | -$300.7M |
| Interest Expense | $42000 | 0 | $469000 | $1.6M | $2.1M | $3.6M | $6.9M | $13.8M | $12.4M | $28.5M |
| Pre-tax Income | -$18.0M | -$14.1M | -$19.8M | -$34.9M | -$40.1M | -$42.5M | -$60.7M | -$147.7M | -$176.2M | -$330.3M |
| Income Tax | -$3.5M | -$2.7M | -$4.0M | -$4.3M | -$2.6M | 0 | 0 | 0 | 0 | $5.8M |
| Net Income | -$14.3M | -$11.2M | -$15.8M | -$30.6M | -$37.6M | -$42.5M | -$60.7M | -$147.7M | -$176.2M | -$336.1M |
| EPS | $-1.48 | $-1.14 | $-1.56 | $-2.51 | $-2.62 | $-2.75 | $-3.18 | $-3.43 | $-2.80 | $-4.65 |
| EPS (Diluted) | $-1.47 | $-1.13 | $-1.55 | $-2.51 | $-2.62 | $-2.75 | $-3.18 | $-3.43 | $-2.80 | $-4.65 |
| Shares Outstanding (Diluted) | $9.7M | $9.9M | $10.2M | $12.2M | $14.3M | $15.5M | $19.1M | $43.1M | $63.0M | $69.5M |
Price
| Price | $106.37 |
| Market Cap | $7.8B |
| Exchange | NASDAQ |
| Country | FR |
Related companies: AXSM · CORT · CYTK · HALO · JAZZ · MDGL · MRUS
Explore sector: Healthcare · Biotechnology
More sections of ABVX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks